Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center
- DOI
- 10.1186/s43046-020-00025-5
- Published
- 2020-03-04
- Container
- Journal of the Egyptian National Cancer Institute
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s43046-020-00025-5,
title = {Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center},
author = {Salah Fayaz and Heba El-Sayed Eissa and Gerges Attia Demian},
year = {2020},
journal = {Journal of the Egyptian National Cancer Institute},
doi = {10.1186/s43046-020-00025-5},
url = {https://doi.org/10.1186/s43046-020-00025-5}
}RIS
TY - JOUR TI - Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center AU - Salah Fayaz AU - Heba El-Sayed Eissa AU - Gerges Attia Demian PY - 2020 JO - Journal of the Egyptian National Cancer Institute DO - 10.1186/s43046-020-00025-5 UR - https://doi.org/10.1186/s43046-020-00025-5 ER -
APA
Fayaz, S., Eissa, H. E., & Demian, G. A. (2020). Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center. Journal of the Egyptian National Cancer Institute. https://doi.org/10.1186/s43046-020-00025-5
Source records
- crossref · retrieved 2026-09-25T22:58:02.507Z